Skip to Main Content

Happy Friday, everyone! This is Elizabeth Cooney, sitting in for Ed Silverman this fine morning. Remember when summer was a slow season for news? No? Either way, here are some items to bolster our case.

A panel of medical experts convened by the Institute of Clinical and Economic Review unanimously voted that there is no evidence to suggest Biogen’s (BIIB) recently approved Alzheimer’s drug offers patients any health benefits beyond the usual care, STAT reports. The 15-to-0 vote also amounted to a rebuke of the Food and Drug Administration, whose officials appeared to bend over backwards to endorse Aduhelm, citing the vast unmet medical need facing the estimated 6 million Americans suffering from Alzheimer’s disease. ICER recently determined the worth of the new Biogen drug is no more than $8,400.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment